LYON, FRANCE, March 8, 2017 – EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that the prestigious Focused Ultrasound Foundation, based in Charlottesville, VA, designated long-term academic French partner INSERM LabTAU a Center of Excellence.

EDAP and INSERM Laboratory of Therapeutic Applications of Ultrasound (LabTAU), in conjunction with the University Hospital Edouard Herriot in Lyon, have been collaborating closely for the past 27 years in the development and use of therapeutic ultrasound in the treatment of kidney stones and localized prostate cancer. These strategic interfaces resulted in the successful marketing of Sonolith®, Ablatherm® Robotic-HIFU and Focal One® worldwide. So far, more than 45,000 prostate cancer patients have been treated using our HIFU technology. EDAP and INSERM LabTAU are currently pursuing on-going development projects using HIFU for therapeutic applications beyond prostate cancer.

Dr. Cyril Lafon, Ph.D., Director of LabTAU, commented: "INSERM LabTAU and EDAP privileged partnership is a valuable example of a fruitful and successful cooperation between academic scientists and a medical device company. Our expertise and advancements are complementary thus accelerating the availability of such non-invasive technology as HIFU to patients."
"LabTAU at INSERM is a pioneering site for research and development in focused ultrasound. They have a long history of establishing how focused ultrasound interacts with tissue, and they use that information to develop innovative clinical applications," says Foundation Chairman Neal F. Kassell, MD. "Their laboratory research has resulted in a number of commercially available products - including those used for the first focused ultrasound treatment for patients with prostate cancer."

Marc Oczachowski, EDAP TMS Chief Executive Officer, concluded: "We are very enthusiastic and proud of the nomination of our privileged partner INSERM LabTAU as Center of Excellence by the prestigious Focused Ultrasound Foundation. It is a recognition of INSERM's highly qualified research work on therapeutic ultrasound. The designation validates our successful collaboration in developing HIFU and ensuring that our co-advancements benefit patients. We at EDAP remain dedicated to making HIFU a standard of care in the treatment of particular types of tumors."

For more information on the designation of INSERM LabTAU as Center of Excellence, please refer to the Focused Ultrasound release: https://www.fusfoundation.org/news/1882-new-center-of-excellence-focuses-on-collaborations-and-education.

Ultrasound Homepage